Sangamo BioSciences, Inc. (SGMO) news stock charts
Sangamo BioSciences, Inc. (SGMO) Investment Summary:
We are a leader in the research, development and commercialization of zinc finger DNA-binding proteins (ZFPs), a naturally occurring class of proteins, and have used our knowledge and expertise to develop a proprietary technology platform. ZFPs can be engineered (see Fig. 1) to make ZFP transcription factors, or ZFP TFs ™, proteins that can be used to turn genes on or off, and ZFP nucleases, ZFNsTM, proteins that enable us to modify DNA sequences in a variety of ways. As ZFPs act at the DNA level, they have broad potential applications in several areas including human therapeutics, plant agriculture, research reagents and cell-line engineering. The main focus for our company is the development of novel human therapeutics and we are building a pipeline of ZFP Therapeutics™. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f03%2f0001193125-08-044052.html#FIS_BUSINESS"www.sangamo.com
Founded in 1995
SANGAMO BIOSCIENCES INC (SGMO:NASDAQ)
LAST $5.85 USD
CHANGE TODAY -0.09 -1.52%
VOLUME 90.2K
As of 5:20 PM 03/15/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of SANGAMO BIOSCIENCES INC (SGMO)
|
OPEN
$5.95
|
PREVIOUS CLOSE
$5.94
|
|
|
DAY HIGH
$5.98
|
DAY LOW
$5.81
|
|
|
52 WEEK HIGH
09/21/09 - $9.39
|
52 WEEK LOW
05/6/09 - $3.40
|
|
|
MARKET CAP
263.3M
|
AVERAGE VOLUME 10 D
176.0K
|
|
|
EPS TTM
$-0.45
|
SHARES OUTSTANDING
45.0M
|
|
|
SGMO Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
The Weird World of ETFs
02/08/2007 12:00 AM ET
The proliferation of exchange-traded funds has led to the creation of increasingly specialized products. Here are some of the most exotic
Key developments for SANGAMO BIOSCIENCES INC (SGMO)
Sangamo Biosciences Inc. Presents at The Annual Lorne Genome Conference 2010, Feb-16-2010
02/10/2010
Sangamo Biosciences Inc. Presents at The Annual Lorne Genome Conference 2010, Feb-16-2010. Venue: Mantra Erskine Beach Resort, Lorne, Victoria, Australia. Speakers: Philip D. Gregory, Vice President of Research.
Sangamo Biosciences Inc. expected to Report Q1 2010 Results on April 30, 2010. This event was calculated by Capital IQ (Created on February 3, 2010).
02/3/2010
Sangamo Biosciences Inc. expected to Report Q1 2010 Results on April 30, 2010. This event was calculated by Capital IQ (Created on February 3, 2010).
Sangamo Biosciences Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2009
02/3/2010
Sangamo Biosciences Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. For the fourth quarter, the company reported net loss of $2.4 million or $0.05 per basic and diluted share compared to a net loss of $2.6 million or $0.06 per basic and diluted share for the same period in 2008. Revenues were $10.2 million compared to $6.8 million for the same period in 2008. Fourth quarter 2009 revenues were from the company's collaboration agreements with Sigma-Aldrich Corporation and Dow AgroSciences. The revenue recognized for the fourth quarter of 2009 consisted of $10.2 million in collaboration agreements and $70,000 in research grants. The increase in revenues was primarily due to the license payment of $15.0 million received from Sigma-Aldrich as part of its expanded agreement with the company which provides Sigma exclusive rights to develop and distribute zinc finger DNA-binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Loss from operations was $2.42 million compared to $2.2 million reported a year ago. For the year, the net loss was $18.6 million or $0.44 per basic and diluted share compared to a net loss of $24.3 million or $0.60 per basic and diluted share for the year ended December 31, 2008. Revenues were $22.2 million compared to $16.2 million in 2008. The increase in revenues for 2009 was primarily attributable to revenues from the company's expanded agreement with Sigma-Aldrich. Loss from operations was $19.40 million compared to $25.37 million reported a year ago.
Sangamo BioSciences, Inc. financial resources
SGMO Competitors
| Company | Last | Change |
| Cellectis | €9.83 EUR | -0.22 |
| Facet Biotech Corp | $27.00 USD | -0.01 |
| GenVec Inc | $2.94 USD | +0.09 |
| Targeted Genetics Corp | $0.20 USD | +0.02 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | SGMO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 12.0x |
|
| Price/Book | 5.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 9.9x |
|
|
SGMO |
||
|
SGMO transactions
| Type Date |
Target |
|
Private Placement
October 2, 2009 |
-- |
More Recent Financial News About Sangamo BioSciences, Inc.
Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
2010-03-04 06:49:23
Quote: Press ReleaseSource: Sangamo BioSciences, Inc.On Wednesday March 3, 2010, 4:05 pm EST/PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: - A live webcast of the presentation will be available on the Sangamo BioSciences website in the Investor Relations section Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeuticâ„¢ development program is currently in a Ph...Read article
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 1 Safety Trial of SB-728-T for HIV/AIDS
2010-02-23 04:29:46
Quote: 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis." Sangamo's collaborator, Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute ...Read article
Sangamo BioSciences Advances ZFP Therapeutic(TM) Pipeline
2010-02-23 04:29:46
Quote: 11 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF). Edward Lanphier, Sangamo's president and CEO, will provide an update on the company's ZFP Therapeutic(TM) pipeline and an overview of t...Read article
Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
2010-02-23 04:29:45
Quote: Press ReleaseSource: Sangamo BioSciences, Inc.On Wednesday January 27, 2010, 4:05 pm ESTThe conference call dial-in numbers are 888-819-8046 for domestic callers and 913-312-0671 for international callers. The passcode for the call is 7172741. Â Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for ther...Read article
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
2010-02-23 04:29:44
Quote: 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2009 financial results and accomplishments and provided an outlook for 2010. For the fourth quarter ended December 31, 2009, Sangamo reported a consolidated net loss of $2.4 million, or $0.05 per share, compared to a net loss of $2.6 million, or $0.06 per share, for the same period in 2008. As of December 31, 2009, the company had cash, cash equivalents, marketable securities and inte...Read article
Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
2010-02-23 04:29:44
Quote: Press ReleaseSource: Sangamo BioSciences, Inc.On Monday February 1, 2010, 4:05 pm ESTThe presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Â The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety...Read article
Q4 2009 Sangamo BioSciences Earnings Release - After Market Close
2010-02-04 03:30:11
Quote: Read article
Sangamo BioSciences, Inc. Q4 2009 Earnings Call Transcript
2010-02-04 03:30:10
Quote: Sangamo BioSciences, Inc. (SGMO)
Q4 2009 Earnings Call Transcript
February 3, 2010 5:00 pm ET
Executives
Elizabeth Wolff – Director, Corporate Communications
Edward Lanphier – President & CEO
Ward Wolff – EVP & CFO
Dale Ando – VP, Therapeutic Development & Chief Medical Officer
Analysts
Charles Duncan – JMP Securities
Liana Moussatos – Wedbush Securities
Mike Smith [ph] – Leerink Swann
Alastair Mackay – GARP Research & Secur...Read article
SANGAMO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
2010-02-04 03:30:10
Quote: SANGAMO BIOSCIENCES INCRequest a Trial to NEW EDGAR Online Pro
Form
8-K for
SANGAMO BIOSCIENCES INC
3-Feb-2010Results of Operations and Financial Condition, Financial Statements and E
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers i...Read article
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
2010-02-04 03:30:10
Quote: 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2009 financial results and accomplishments and provided an outlook for 2010. For the fourth quarter ended December 31, 2009, Sangamo reported a consolidated net loss of $2.4 million, or $0.05 per share, compared to a net loss of $2.6 million, or $0.06 per share, for the same period in 2008. As of December 31, 2009, the company had cash, cash equivalents, marketable securities and inte...Read article
Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
2010-02-02 03:34:46
Quote: Press ReleaseSource: Sangamo BioSciences, Inc.On Monday February 1, 2010, 4:05 pm ESTThe presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Â The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety...Read article
Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
2010-01-28 04:57:33
Quote: Press ReleaseSource: Sangamo BioSciences, Inc.On Wednesday January 27, 2010, 4:05 pm ESTThe conference call dial-in numbers are 888-819-8046 for domestic callers and 913-312-0671 for international callers. The passcode for the call is 7172741. Â Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for ther...Read article
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 1 Safety Trial of SB-728-T for HIV/AIDS
2010-01-20 02:51:52
Quote: 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis." Sangamo's collaborator, Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute ...Read article
Sangamo BioSciences Advances ZFP Therapeutic(TM) Pipeline
2010-01-12 03:09:04
Quote: 11 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF). Edward Lanphier, Sangamo's president and CEO, will provide an update on the company's ZFP Therapeutic(TM) pipeline and an overview of t...Read article
Sangamo plans another mid-stage neuropathy trial
2010-01-12 03:09:03
Keywords: United States of America,Commercial services and supplies (industry group),Industrial machinery,Machinery,Pharmaceuticals (sub-industry),Biotechnology,Healthcare,Company News item,Economic news, EC, business/financial pages,
Quote: Sangamo plans another mid-stage neuropathy trial
LOS ANGELES, Jan 11 (Reuters) - Sangamo BioSciences Inc
(SGMO.O) said on Monday it will conduct a Phase 2b trial of
experimental drug SB-509 as a treatment for diabetic
neuropathy, as it continues to seek a development partner for
pivotal trials of the product. Sangamo develops DNA-binding "zinc finger" proteins to
modify and regulate genes. SB-509 is a zinc finger activator of
vascular endothelial growth factor, which has been shown to
promote t...Read article
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
2010-01-07 04:54:26
Quote: Press ReleaseSource: Sangamo BioSciences, Inc.On Wednesday January 6, 2010, 4:05 pm ESTThe presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Â The most advanced ZFP Therapeuticâ„¢ development program is currently in Phase 2 clinical trials for evaluation of saf...Read article
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
2009-12-11 05:19:26
Quote: Read article
Sangamo drug helps muscle in 1/3 of ALS patients
2009-12-11 05:19:25
Quote: Sangamo drug helps muscle in 1/3 of ALS patients * 17 pct of historical controls had muscle improvement * No data on magnitude of gains By Deena Beasley LOS ANGELES, Dec 9 (Reuters) - Nearly a third of
amyotrophic lateral sclerosis (ALS) patients treated with an
experimental drug from Sangamo BioSciences Inc (SGMO.O) had
muscle improvement, according to preliminary mid-stage study
results announced on Tuesday. The small Phase 2 study showed that six out of 19, or 32
percent, of patients injected...Read article
Sangamo says early data from ALS study is positive
2009-12-11 05:19:24
Quote: (AP) -- Sangamo Biosciences Inc. said Wednesday that early data from a clinical trial shows its Lou Gehrig's disease drug candidate improved patients' muscle function.Patients who were injected with the drug SB-509 were about twice as likely to have improved muscular function, Sangamo said. It reported that 32 percent of patients who received SB-509 had improved muscle function, compared to 17 percent of patients who took standard treatments.A total of 19 patients received two injections of SB-5...Read article
Sangamo BioSciences Announces Presentation at Merriman Curhan Ford's Investor Summit 2009
2009-11-30 05:11:54
Quote: These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics.Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP ...Read article
Would you like to leave a comment about Sangamo BioSciences, Inc. SGMO
Find out what social network information about Sangamo BioSciences, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Sangamo BioSciences, Inc.'s Stock there is more great penny stock and market information at Realpennies